Mapping the alterations in glutamate with GluCEST MRI in a mouse model of dopamine deficiency

Glutamate chemical exchange saturation transfer (GluCEST) MRI was used to measure metabolic changes in mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) by mapping regional cerebral glutamate. The GluCEST contrast following MPTP treatment was correlated with 1H‐MR spectroscopy, motor function, and immunohistochemical measures. The GluCEST contrast was found to be significantly higher in the striatum and motor cortex of mice treated with MPTP than in controls (p < 0.001), which was confirmed by localized 1H‐MR spectroscopy. Elevated striatal GluCEST was positively associated with local astrogliosis measured by immunohistochemistry for glial fibrillary acidic protein. Additionally, a negative correlation was found between motor function, measured by the four‐limb grip strength test, and GluCEST of the striatum (R = −0.705, p < 0.001) and the motor cortex (R = −0.617, p < 0.01), suggesting a role of elevated glutamate in the abnormal cerebral motor function regulation. The GluCEST contrast and glial fibrillary acidic protein immunostaining were unaltered in the thalamus indicating glutamate elevation was localized to the striatum and the motor cortex. These findings suggest that in addition to measuring spatial changes in glutamate, GluCEST may serve as an in vivo biomarker of metabolic and functional changes that may be applied to the assessment of a broad range of neuropathologies.

[1]  F. Durif,et al.  Does MPTP intoxication in mice induce metabolite changes in the nucleus accumbens? A 1H nuclear MRS study , 2013, NMR in biomedicine.

[2]  John A. Detre,et al.  Magnetic Resonance Imaging of Glutamate , 2011, Nature Medicine.

[3]  R. Matsuda,et al.  1-Syntrophin–deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration , 2002 .

[4]  J. Langston,et al.  Effects of 1‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine and 1 ‐Methyl‐4‐Phenylpyridinium Ion on ATP Levels of Mouse Brain Synaptosomes , 1990, Journal of neurochemistry.

[5]  P. Bagga,et al.  In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment , 2013, Journal of neurochemistry.

[6]  P. Bagga,et al.  Regional cerebral metabolism in mouse under chronic manganese exposure: Implications for Manganism , 2012, Neurochemistry International.

[7]  V. Tiwari,et al.  Glutamatergic and GABAergic TCA Cycle and Neurotransmitter Cycling Fluxes in Different Regions of Mouse Brain , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  R. Schwarting,et al.  MPTP Susceptibility in the Mouse: Behavioral, Neurochemical, and Histological Analysis of Gender and Strain Differences , 2000, Behavior genetics.

[9]  F. Durif,et al.  Proton MR Spectroscopy for Diagnosis and Evaluation of Treatment Efficacy in Parkinson Disease. , 2016, Radiology.

[10]  C. Adler,et al.  Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. , 2013, Brain : a journal of neurology.

[11]  Allan R. Jones,et al.  A mesoscale connectome of the mouse brain , 2014, Nature.

[12]  C. Meshul,et al.  l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 2005, Neuroscience.

[13]  J. Gazewood,et al.  Parkinson disease: an update. , 2013, American family physician.

[14]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[15]  John A. Detre,et al.  In vivo measurement of glutamate loss is associated with synapse loss in a mouse model of tauopathy , 2014, NeuroImage.

[16]  Uzay E. Emir,et al.  Elevated Pontine and Putamenal GABA Levels in Mild-Moderate Parkinson Disease Detected by 7 Tesla Proton MRS , 2012, PloS one.

[17]  Evaluation of Nigrostriatal Neurodegeneration and Neuroinflammation Following Repeated Intranasal 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Administration in Mice, an Experimental Model of Parkinson’s Disease , 2013, Neurotoxicity Research.

[18]  Ravinder Reddy,et al.  Imaging of glutamate in the spinal cord using GluCEST , 2013, NeuroImage.

[19]  J. Obeso,et al.  Pathophysiology of the basal ganglia in Parkinson's disease , 2000, Trends in Neurosciences.

[20]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[21]  N. Danbolt.  Glutamate uptake , 2001, Progress in Neurobiology.

[22]  Ravinder Reddy,et al.  Imaging of glutamate neurotransmitter alterations in Alzheimer's disease , 2013, NMR in biomedicine.

[23]  G. E. Alexander.  Basal Ganglia‐Thalamocortical Circuits: Their Role in Control of Movements , 1994, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[24]  R. Ramsay,et al.  Studies on the Characterization of the Inhibitory Mechanism of 4′‐Alkylated 1‐Methyl‐4‐Phenylpyridinium and Phenylpyridine Analogues in Mitochondria and Electron Transport Particles , 1994, Journal of neurochemistry.

[25]  Haley K Holmer,et al.  Dietary restriction affects striatal glutamate in the MPTP‐induced mouse model of nigrostriatal degeneration , 2005, Synapse.

[26]  Brian Litt,et al.  Glutamate imaging (GluCEST) lateralizes epileptic foci in nonlesional temporal lobe epilepsy , 2015, Science Translational Medicine.

[27]  Philippe Hantraye,et al.  The Neuroprotective Agent CNTF Decreases Neuronal Metabolites in the Rat Striatum: An in Vivo Multimodal Magnetic Resonance Imaging Study , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  A. Ruifrok,et al.  Quantification of histochemical staining by color deconvolution. , 2001, Analytical and quantitative cytology and histology.